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Abstract
This paper explores the emergence of the importance of knowledge in Risk-Based Decision
Making (RBDM) and Quality Risk Management (QRM) through a detailed review of ICH Q9(R1)
(Step 2) and presents a framework(the RKI cycle) to integrate knowledge and risk and
associated six principles to operationalise it.

1. Introduction
In August 2002, the United States pharmaceutical regulatory authority, the US Food & Drug
Administration (FDA), announced the Pharmaceutical cGMPs1 for the 21st Century Initiative
promoting:
“A science and risk-based approach to product quality regulation incorporating an
integrated quality systems approach.”
The emphasis in this approach was on science and risk, and this was the impetus for the formation
of the Pharmaceutical Regulatory Science Team (PRST) in TU Dublin (PRST, 2020) which, since
2005, has been active in developing patient-focused strategies, frameworks, models and tools to
ensure the availability of high-quality medicinal products through research and engagement with
global industry and regulators. PRST research has focused on a variety of topics central to
pharmaceutical product quality, including quality risk management, knowledge management,

1

Current good manufacturing processes
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operational excellence, risk-based decision making, challenges with post-approval change
management, and more.
In a 2014, PRST members, in an article entitled: ‘From Science to Knowledge: An Overview of the
Evolution of Knowledge Management in Regulatory Guidance’ (Greene and O’Donnell, 2014),
discuss the low usage of the term ‘knowledge’ in the FDA’s 21st century initiative, noting that
while ‘science’ is mentioned more than 15 times, ‘knowledge’ is only mentioned once, in a
section under the heading ‘science-based policies and standards’. Furthermore while the PRST
members recognise the inherent relationship between Science and Knowledge, they argue that:
‘If we limit the knowledge we value to that which is aligned with science, which one could
argue is truly ‘explicit knowledge’, one is ignoring a whole range of ‘tacit knowledge’
spanning across the lifecycle of the product’
In the same 2014 article, the PRST members then explored the 2005 guidance on Quality Risk
Management, ICH Q9 (ICH, 2005), through the lens of ‘knowledge’, noting that ICH Q9 identifies
one of the two key principles of quality risk management as:

‘The evaluation of risk to quality should be based on scientific knowledge’

They suggest that a noteworthy aspect of ICH Q9 is a discussion on uncertainty, where the
occurrence of ‘knowledge gaps’ is mentioned. ICH Q9 proposed that uncertainty can be:

‘…..due to a combination of incomplete knowledge about a process and its expected or
unexpected variability. Typical sources of uncertainty include gaps in knowledge, gaps in
pharmaceutical science and process understanding….’
They conclude that by linking science and understanding gaps, to knowledge gaps, knowledge is
emerging as an overarching concept, of which both science and understanding are a subset,
albeit still with a leaning towards explicit knowledge.

https://arrow.tudublin.ie/level3/vol16/iss2/2
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In 2008, the guidance of the Pharmaceutical Quality System, ICH Q10 (ICH, 2008) was published,
and it firmly positioned Quality Risk Management and Knowledge Management as the twin
enablers for an effective Pharmaceutical Quality System (PQS). However, while the topic of
Quality Risk Management (QRM) was assigned a full ICH guideline of its own (i.e., the
aforementioned ICH Q9); Knowledge Management (KM) received somewhat less attention, with
only a single paragraph on it included in ICH Q10, along with some limited additional content in
the related Questions and Answers (ICH, 2010) and Points to Consider (International Conference
on Harmonisation, 2011) document. ICH Q10 provides a definition of knowledge management
(ICH, 2008) as:
“Knowledge management: systematic approach to acquiring, analysing, storing, and
disseminating information related to products, manufacturing process and components.”
In the previous mentioned paper by the PRST members, they observe that in the ICH Q10 KM
definition, it is ‘information’ that ICH Q10 aspires to manage, rather than knowledge. However,
on a deeper dive into ICH Q10, examples of what is considered knowledge (both explicit and tacit)
can be found such as:
‘Development activities, using scientific approaches provide knowledge for product and
process understanding’
Further sources of knowledge identified in ICH Q10 are:
•
•
•
•
•
•
•
•

Prior knowledge (public domain or internally documented)
Pharmaceutical development studies
Technology transfer activates
Process validation studies over the product lifecycle
Manufacturing experience
Innovation
Continual improvement
Change management activities

With the revision of ICH Q9 currently ongoing, the PRST carried out an in-depth analysis of the
following published material associated with the revision, to explore in 2022, how knowledge is
positioned in relation to QRM:
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•

ICH Q9 Revision Concept paper (ICH, 2020)

•

ICH Q9(R1) Draft Guideline (Step 2) (ICH, 2021).

In addition, the PRST, through its relationship with pharmaceutical professional association
bodies and member companies, also had visibility to the ICH (Q9)R1 request for training.

As the focus of this paper, the authors examined published literature from other sources, in
particular seeking to understand the emerging role knowledge plays in Risk-Based Decision
Making (RBDM). The linkage between knowledge and risk in support of RBDM is demonstrated,
and a framework for operationalising these is presented.

2. ICH Q9 revision: Concept paper
The concept paper for ICH Q9(R1) (ICH, 2020), published in November 2020, identified four
primary areas for improvement (items #1 through #4 in the list following), and two additional
points to be addressed (items #5 and #6), henceforth “six revision topics,” namely:
1.
2.
3.
4.
5.

High levels of subjectivity in risk assessments and in QRM outputs
Product availability risks
Lack of understanding as to what constitutes formality in QRM work
Lack of clarity on risk-based decision-making
Additional clarity on the expectations relating to keeping risk assessments current and on
the implementation of risk review activities
6. Change ‘risk identification’ to ‘hazard identification’
While knowledge or knowledge management was not explicitly mentioned in these six revision
topics, it is the authors’ experience that both are fundamental enablers to progress a majority of
these topics.

3. ICH Q9(R1) Draft Guideline (Step 2)

https://arrow.tudublin.ie/level3/vol16/iss2/2
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Turning attention now to the ICH Q9(R1) draft revision published in December 2021 (ICH, 2021)
for public consultation2, the authors carried out an in-depth analysis of the document for
references to knowledge and knowledge management as an enabler to QRM, and by extension,
to any of the six revision topics. The analysis identified that a key concept in the draft ICH Q9(R1)
is that knowledge informs decisions about risk, through its many references to knowledge
management in relation to QRM and Risk-Based Decision Making. The following are related
excerpts from the draft guideline that demonstrate this premise (Table A).
Table A - Summary of excerpts from the draft ICH Q9(R1) identifying requirements for knowledge and knowledge
management

ICH Q9(R1) Step 2
Section
Introduction

Section 4.1 on
Responsibilities includes
guidance on subjectivity

Section 4.3 on Risk
Assessment includes
guidance on Hazard
identification.

Section 4.6 on Risk
Review
Section 5.1 on Formality

Relevant excerpts (emphasis in bold added by the authors)
In the development phase, quality risk management is part of building
knowledge and understanding risk scenarios, so that appropriate risk control
can be decided upon during technology transfer, for use during the commercial
manufacturing phase. In this context, knowledge is used to make informed
risk-based decisions, trigger re-evaluations and stimulate continual
improvements.
Subjectivity can impact every stage of a quality risk management process,
especially the identification of hazards and estimates of their probabilities of
occurrence, the estimation of risk reduction and the effectiveness of decisions
made from quality risk management activities… While subjectivity cannot be
completely eliminated from quality risk management activities, it may be
controlled by addressing bias, the proper use of quality risk management tools
and maximising the use of relevant data and sources of knowledge.
Decision makers should assure that a quality risk management process is
defined, deployed and reviewed and that adequate resources and knowledge
are available.
Hazard identification is a systematic use of information [knowledge] to
identify hazards referring to the risk question or problem description.
Information [knowledge] can include historical data, theoretical analysis,
informed opinions, and the concerns of stakeholders.
The passage specifically cites ‘information’, but upon examination, these
examples are equally considered and often referred to as knowledge
The output/results of the risk management process should be reviewed to
take into account new knowledge and experience
The term “uncertainty” in quality risk management means lack of knowledge
about risks. The level of uncertainty that is associated with the area being risk
assessed informs how much formality may be required to manage potential

2

In accordance with Step 2 of the ICH guideline development procedure (https://ich.org/page/formal-ichprocedure)
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ICH Q9(R1) Step 2
Section

Relevant excerpts (emphasis in bold added by the authors)
risks. Systematic approaches for acquiring, analysing, storing and
disseminating scientific information are essential for generating knowledge,
which in turn informs all quality risk management activities. Uncertainty may
be reduced via effective knowledge management, which enables accumulated
and new information (both internal and external) to be used to support riskbased decisions throughout the lifecycle.

Section 5.2 on RiskBased Decision Making

Chapter 6 on Product
Availability Risks

Regardless of how much formality is applied, the robust management of risk is
the goal of the process. This should be based on evidence, science and
knowledge, where risk scores, ratings or assessments are supported by data or
by an appropriate justification or rationale.
Approaches to risk-based decision-making are beneficial, because they address
uncertainty through the use of knowledge, facilitating informed decisions by
regulators and the pharmaceutical industry in a multitude of areas, including
when allocating resources. They also help recognize where uncertainty
remains, so that appropriate risk controls (including improved detectability)
may be identified to enhance understanding of those variables and further
reduce the level of uncertainty.
As all decision making relies on the use of knowledge, see ICH Q10 for
guidance in relation to Knowledge Management2. It is important also to
ensure the integrity of the data that are used for risk-based decision making.
An effective pharmaceutical quality system drives both supply chain
robustness and sustainable GMP compliance. It also uses quality risk
management and knowledge management to provide an early warning
system that supports effective oversight and response to evolving
quality/manufacturing risks from the pharmaceutical company or its external
partners.
Approval and oversight of outsourced activities and material suppliers is
informed by risk assessments, effective knowledge management, and an
effective monitoring strategy for supply chain partner performance.

Furthermore, the ICH Informational Presentation on the ICH Q9(R1) revision (ICH, 2021) highlights
the opportunity to further connect & align ICH Q9 to ICH Q10 (ICH, 2008), ICH Q8 (ICH, 2009)
and ICH Q12 (ICH, 2019) as follows (emphasis in bold added by the authors):
“These cross-references to ICH Q10 [in relation to KM] serve to highlight the importance
of using available sources of knowledge (e.g., pharmaceutical development studies,
process validation studies, change management activities, etc.) and Knowledge
Management in general during QRM activities.

https://arrow.tudublin.ie/level3/vol16/iss2/2
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It is considered that the new guidance in ICH Q9(R1) supports the existing guidance in ICH
Q8 and Q10, as well as ICH Q12 and other Quality Guidelines. Those other Guidelines all
rely, to some extent, on the application of quality risk management principles.”
The draft guideline also contains text from the original version (ICH, 2005), which draws an
important and clear correlation between the concept of uncertainty and knowledge, indicating
uncertainty is due to incomplete knowledge (emphasis in bold added by authors).
“Uncertainty is due to combination of incomplete knowledge about a process and its
expected or unexpected variability. Typical sources of uncertainty include gaps in
knowledge, gaps in pharmaceutical science and process understanding, sources of harm
(e.g., failure modes of a process, sources of variability), and probability of detection of
problems.”
The draft revised guideline furthermore reinforces this concept in the following text:
“Uncertainty: The term “uncertainty” in quality risk management means lack of
knowledge about risks. The level of uncertainty that is associated with the area being risk
assessed informs how much formality may be required to manage potential risks.
Systematic approaches for acquiring, analysing, storing and disseminating scientific
information are essential for generating knowledge, which in turn informs all quality
risk management activities. Uncertainty may be reduced via effective knowledge
management, which enables accumulated and new information (both internal and
external) to be used to support risk-based decisions throughout the lifecycle.”
The correlation of the application of knowledge and risk having an inverse relationship was
discussed by one of the authors of this paper, in his PhD thesis (Lipa, 2021) and is illustrated in
the diagram below (Figure 1).

Published by ARROW@TU Dublin, 2022
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Figure 1 - Risk Varies Inversely with Knowledge Application

From Figure 1 one can see that risk is a function of knowledge and how increased knowledge
leads to increased understanding, lower uncertainty, and therefore to lower risk.

4. ICH Q9(R1) Stakeholder Submission Form – Suggested Case Studies
/ Training Materials
At the initiation of the public consultation phase for the draft ICH Q9(R1) guideline, the ICH
Q9(R1) Expert Working Group (EWG) issued a call for training materials in the format of a
Stakeholder Submission Form. This call addressed specific topics of training material that the
EWG were seeking, based on the six revision topics identified in the concept paper as:
1.
2.
3.
4.
5.
6.

Subjectivity in QRM
Product Availability Risks
Formality in QRM
Risk-Based Decision Making
Risk Review
Hazard Identification

https://arrow.tudublin.ie/level3/vol16/iss2/2
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Specific learning goals for each of these six revision topics were identified and detailed in the
Stakeholder Submission Form, providing valuable insight into the EWG’s thinking on key priorities
to address with the revision, and indeed to realise the benefits, of QRM.

Figure 2 below, drawn by the authors, provides a summary of the revision topics and the
associated learning goals. Some of the learning goals have been abridged by the authors for
brevity.

Figure 2 - ICH Q9(R1) Learning Goals Overview

The PRST undertook a detailed analysis of these learning goals with a view to mapping which
revision topics and learning goals would be enhanced by knowledge and knowledge management
activities.

The following learning goals specifically identified knowledge or knowledge

management as an element:
•
•
•
•

Learning goal 2.B:
and distribution
Learning goal 4.A:
Learning goal 4.B:
Learning goal 5.A:

Published by ARROW@TU Dublin, 2022
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What is Risk-Based Decision Making
Structured approaches to RBDM
What is risk review and why it is important
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•

4.

Learning goal 6.D: How hazard identification can be facilitated by lifecycle knowledge
management and risk review

The emerging role knowledge plays in support of effective RBDM

In addition to focusing on KM and QRM, the PRST is active in research involving effective RBDM
as illustrated by another paper in this special edition of Level 3, Steps Beyond Risk Assessment in
QRM: RBDM, the Next Horizon (Mulholland, Greene and Lipa, 2021).

This research journey has identified interdependencies between all three topics (i.e., KM, QRM
and RBDM), and indeed knowledge management is emerging as a key enabler of RBDM, and
RBDM is, of course, a fundamental output of all QRM activities.

In the paper listed above, and in anticipation of the release of ICH Q9(R1), the authors noted that
the 2020 ICH Q9(R1) Concept Paper (ICH, 2020) expressed concern with a ‘lack of clarity’ on what
RBDM actually means. Consequently, they performed an exhaustive literature review into RBDM
across other sectors, including those regarded as High Reliability Organisations (HROs),
Mulholland et al. formulated a list of Twenty-one attributes commonly applied to RBDM shown
below in Figure 3. These criteria were sorted under the headers of Governance, Process (each
QRM and KM) and People. These categorisations were chosen to align with the ‘Pillars of
Knowledge Management’ utilised by KM practitioners and referenced in the ISPE3 Good Practice
Guide to Knowledge Management in the Pharmaceutical Industry (ISPE, 2021).

3

International Society of Pharmaceutical Engineers.
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Figure 3 – Compilation of twenty-one attributes of RBDM from reviewed sources

Of the twenty-one attributes commonly applied to RBDM, eight of those (identified in orange in
Figure 3) are potentially addressed by KM processes, thus highlighting the role knowledge and
knowledge management play as an enabler to RBDM. In addition, it was noted following the
release of ICH Q9(R1), that a strong connection with knowledge was made in the ICH Q9(R1)
proposed definition of RBDM as follows:
“An approach or process that considers knowledge about risks relevant to the decision and
whether risks are at an acceptable level”
These insights are useful to expand one’s thinking about how a focus on KM can in fact improve
RBDM.

5. A framework to unite knowledge and risk
Having identified the important role knowledge plays in QRM, and concurrently RBDM, the need
to provide a mechanism to integrate these topics is paramount.

Recently, the PRST has advanced research on the integration of these topics. One outcome of
this research was the development of a framework to purposefully unite quality risk
management and knowledge management (Lipa, O’Donnell and Greene, 2020a).

Published by ARROW@TU Dublin, 2022
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framework, which has been termed the Risk-Knowledge Infinity Cycle (RKI Cycle), is depicted in
Figure 4, and is based on the following key concepts:
•

Knowledge is both an input to and an output from quality risk management

•

Knowledge has an inverse relationship with risk

•

Concept of flow; knowledge flows effortlessly and on demand to inform risk, and risk
informs new knowledge

•

The cycle is continuous and perpetual; knowledge is always evolving and should be
continually applied to inform one’s understanding of risk

•

The cycle applies across the product lifecycle, and over time, as knowledge increases
through development activities, experience and other means, the knowledge can be
applied to increase understanding, reduce uncertainty, and therefore to reduce risk.

RISK

KNOWLEDGE

© Lipa & O’Donnell 2020

Figure 4 - The Risk-Knowledge Infinity Cycle (RKI Cycle)

The research findings also revealed a stark disconnect between quality risk management and
knowledge management (Lipa, O’Donnell and Greene, 2021). In February 2021, when a cohort of
industry stakeholders and regulatory authorities were surveyed on how connected QRM and KM
should be, there was near unanimous agreement (97%) that the practices should be tightly
connected. However, when queried on how connected QRM and KM are in practice, none of the
survey participants indicated that QRM and KM were fully integrated – see Figure 5 below.

https://arrow.tudublin.ie/level3/vol16/iss2/2
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Figure 5 - QRM-KM integration in theory vs. practice

Given that QRM and KM are the means to operationalise how organisations respectively manage
risk and knowledge, and recognising the expectation and the need to ensure that knowledge
informs risk and risk informs knowledge, as highlighted throughout regulatory guidance
documents and benchmarking with other industries (Lipa, O’Donnell and Greene, 2020b),
thoughtfully uniting these enablers is arguably urgent and important.
The RKI Cycle was designed in August 2020 (prior to the issuance of the ICH Q9(R1) concept paper
in November 2020) to address this very challenge – the integration between QRM and KM, in
order to ensure the best possible knowledge is available for QRM activities, and that knowledge
generated through QRM activities is effectively managed. When asked if a framework such as
the RKI Cycle can improve QRM-KM integration, 90% of survey participants agreed (Lipa,
O’Donnell and Greene, 2021). Furthermore, when asked about potential benefits, the following
represent the top reported benefits of having QRM and KM well integrated:
•
•
•
•
•
•

Better risk-based decisions – where decisions are informed by risk and knowledge
More data/knowledge-driven risk assessments
Increased ability to leverage off of prior knowledge
Improved control strategies – which better reflect risk and knowledge
Improved PQS effectiveness – where an integrated approach to risk and knowledge
supports decision making, validation, change management, out-sourcing, etc.
Improved protection and value for patients (reduced risks of defects, drug shortages,
etc.)

Published by ARROW@TU Dublin, 2022
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Notably, several of these benefits associated with deploying a framework such as the RKI Cycle –
including better risk-based decisions, more data/knowledge driven risk assessments, use of prior
knowledge, PQS effectiveness and improved protection for patients – are closely aligned with the
draft guidance subsequently issued in December 2021 in ICH Q9(R1) (ICH, 2021) and the learning
goals identified in the associated training. The authors suggest that the RKI Cycle could be an
operational solution to enhance the realisation of QRM to the benefit of the patient.

6. A Vision: How the RKI Cycle framework enhances RBDM
Given the inherent alignment between the anticipated benefits of implementing the RKI Cycle
and the aforementioned expectations of ICH Q9(R1) (ICH, 2021), the training goals, and role KM
plays in RBDM, the authors propose the following vision as depicted in Figure 6:

Figure 6 - A Vision for how the RKI Cycle framework enhances RBDM

In returning to the literature review and analysis, considering the knowledge and knowledge
management requirements identified in the ICH Q9(R1) draft guideline, in the call for training
proposals, and in the RBDM literature, the authors recognised the potential impact of the RKI
Cycle in meeting the goals of ICH Q9(R1) realisation; this impact is both “deep and broad.”

https://arrow.tudublin.ie/level3/vol16/iss2/2
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First, considering RBDM, inclusive of the relevant literature and the learning goals, the authors
propose that the RKI Cycle can play a deep and foundational role in advancing RBDM, in learning
goals 4.A, 4.B and 4.C as follows:
•

Learning goal 4.A: “To learn what risk-based decision-making is, and how it differs from
just decision making” (abridged to What is RBDM in figures below). Specifically:
o The RKI Cycle addresses how knowledge management throughout the
lifecycle supports effective risk-based decision making, leading to well informed
decisions.
o The RKI Cycle could be seen to be a tool that supports risk based decision making.
o The authors propose that execution of the RKI Cycle provides a methodology that
ensures the most available, up-to-date knowledge is presented to the decisionmaker, and as a result, aids balancing effort, resources and risk during risk-based
decision-making.

•

Learning goal 4.B: “To learn about the different structured approaches to risk-based
decision making that exist, and how and where they might be used” (abridged to
Structured approaches to RBDM in figures below)
o The RKI Cycle is a framework that provides a structured approach to enhance
knowledge flow and availability across the product lifecycle and as such clearly
demonstrates the role of knowledge, linking it with reducing risk and lower
uncertainty.
o Its strength is in ensuring the most available, up to date knowledge is presented
to the decision-maker during the QRM activities.
o The cyclical nature of the RKI Cycle encourages risk review as knowledge increases
over time, through development activities, experience and other means. This
enhanced knowledge can be applied to increase understanding, reduce
uncertainty, and therefore to reduce risk during RBDM.

•

Learning goal 4.C: “To learn how risk assessments and their related calculations (or
estimations) of risk can be linked to the potential for patient harm and other negative
outcomes” (Abridged to Link between RA calculations / estimations and patient harm in
figures below)
o The RKI Cycle reduces inherent uncertainty in risk assessment calculations and
estimations by ensuring the best possible knowledge is applied through KM
practices, thus enabling more accurate risk calculations (or estimations). The
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15

Level 3, Vol. 16, Iss. 2 [2022], Art. 2

cyclical nature of the RKI Cycle can aid RBDM and reduce uncertainty over time at
each iteration of the QRM activities.
Figure 7 provides a visualisation of the deep impact the RKI Cycle can have across the RBDM
learning goals, emphasised with yellow highlighting.

Figure 7 - RKI Cycle as an enabler of ICH Q9(R1) Learning Goal on Risk-Based Decision Making

7. A Vision: How the RKI Cycle framework enhances QRM at large
Considering the learning goals identified for the other five revision topics in ICH Q9(R1),
knowledge and knowledge management were identified as requirements in the following
learning goals, offering broad impact across revision topics (additional connections may exist in
deeper evaluation):
•

Learning goal 2.B: To learn, by means of case studies or examples, how effective QRM
can manage risks related to suppliers, service providers and distribution systems, in the
context of pharmaceutical quality (abridged to How QRM can manage risks related to
suppliers, service providers and distribution systems in figures below)
o The RKI Cycle applied during QRM activities focused on suppliers, service providers
and distribution systems provides a framework to ensure the best possible

https://arrow.tudublin.ie/level3/vol16/iss2/2
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knowledge is available and is applied to manage risks to pharmaceutical quality,
and to help ensure product availability.
•

Learning goal 5.A: To learn what risk review is and why it is an important part of the QRM
process (abridged to What is risk review and why it is important in the figures below)
o The cyclical nature of the RKI Cycle enhances risk review, both in making
knowledge available for risk review and capturing knowledge during risk review.
The RKI Cycle fosters activities to keep knowledge current during risk review and
all QRM activities.

•

Learning goal 6.D: To learn, by means of case studies and examples, how Hazard
Identification can be facilitated by lifecycle knowledge management and Risk Review
activities (abridged to How hazard identification can be facilitated by lifecycle
knowledge management and risk review in the figures below)
o The RKI Cycle facilitates hazard identification by providing a framework inclusive
of lifecycle knowledge management by ensuring the best available knowledge is
available to decision makers, and is captured for future use (e.g., creation of
hazard libraries, lessons learned and access to experts, etc.).

Figure 8 provides a visualisation of the broad impact the RKI Cycle can have across other QRM
revision topics and associated learning goals (in addition to RBDM goals), emphasised in yellow
highlighting.

Figure 8 - RKI Cycle as an enabler to ICH Q9(R1) learning goals beyond RBDM
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Furthermore, considering the text of the draft ICH Q9(R1), there are extensive references to the
importance of knowledge and knowledge management, as summarised earlier in this paper. On
inspection, these references to knowledge and knowledge management identify potential
requirements across all six revision topics in those areas; the authors suggest that the RKI Cycle
may represent a potential solution for addressing those requirements. Indeed, the RKI Cycle
represents an opportunity for achieving a broad impact with regard to the goals of ICH Q9(R1).
Figure 9 provides a visualisation of the broad impact the RKI Cycle can have across each of the six
revision topics as outlined in ICH Q9(R1), emphasised in yellow highlighting.

Figure 9 – RKI Cycle as an enabler across all six ICH Q9(R1) revision topics

Taking these views in aggregate, the following matrix was created by the authors (Figure 10) to
summarise how central the RKI Cycle framework can be to improving RBDM and indeed,
supporting the realisation of the goals of ICH Q9(R1) across all six revision topics. The impact is
deep (i.e., to RBDM) and broad (i.e., touching all six revision topics), as emphasised in the yellow
highlighting in Figure 10.

https://arrow.tudublin.ie/level3/vol16/iss2/2
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Figure 10 - A summary of the potentially “deep and broad” impact of the RKI Cycle on ICH Q9(R1) revision topics
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In fact, one could argue given the pervasive expectations to connect knowledge and risk outlined
in ICH Q9(R1), that the goals of ICH Q9(R1) could be more easily realised by adopting some type
of framework, such as the RKI Cycle, to connect knowledge and risk through knowledge
management and quality risk management; this is important given the current state of
disconnectedness between the two.

8. Operationalisation of the RKI Cycle
Continued effort is well underway to better define the steps necessary for the operationalisation
of the RKI Cycle. This effort will take into account the input received in the aforementioned
feedback survey, where participants were asked about the top actions necessary, and they
provided the following responses (Lipa, O’Donnell and Greene, 2021):
•

Establish practices / procedures to operationalise integration of QRM & KM

•

Define the types of knowledge created by QRM and how this should be managed

•

Develop ways where KM (including tacit knowledge) is a formal input in all risk
assessments and define the types of knowledge required as QRM inputs and where/how
to acquire them

•

Focus more on training staff on KM and its practical application during QRM activities –
(this recognises that QRM has already been the subject of much training across the
industry, but KM probably has not been).

The RKI Cycle as introduced identified 6 nodes on the cycle.

To further enhance the

operationalisation of the RKI Cycle, these nodes have been adapted to principles4 as shown in
Table B below.

4

A fundamental truth or proposition that serves as the foundation for a system of belief or behaviour or for a chain
of reasoning (Oxford Dictionary)

https://arrow.tudublin.ie/level3/vol16/iss2/2

20

Lipa et al.: Improving Risk-Based Decision Making (RBDM) Effectiveness

Table B - A summary of the six principles to support operationalisation of the RKI Cycle

RKI Cycle
Principle
Principle 1
Principle 2
Principle 3
Principle 4
Principle 5
Principle 6

Description
Ensure the best available knowledge flows into the QRM activities
Manage Risk via the QRM process, thus enhancing RBDM
Use KM practices to capture the knowledge outputs of QRM to enhance risk
control, risk communication, risk review and enable knowledge flow
Ensure there is a means to acquire, grow, capture and retain new knowledge
as it emerges or is generated
Manage Knowledge effectively through implementing KM practices
Ensure all knowledge (new and prior) is available to QRM and PQS activities
and all business processes, providing the basis for risk management,
continual improvement and enhanced decision making

Such principles can be used to guide the deployment of the RKI Cycle as they can be used as
‘target conditions,’ or ‘conditions which must be true’ at various points on the RKI Cycle, enabling
the RKI Cycle to be more than a simple ‘loop’, but rather a leading integration framework for risk
and knowledge, and QRM and KM. An adapted RKI Cycle is depicting these principles is shown in
Figure 11.

Figure 11 - RKI Cycle (adapted) depicting six principles to enable operationalisation in support of RBDM

Reflecting on this version of the RKI Cycle, one can see that node 2 advocates effective
implementation of QRM and RBDM, while node 5 advocates effective implementation of KM,
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thus addressing both the enablers to an effective Pharmaceutical Quality System, as described in
ICH Q10.
In addition, the authors suggest that the other 4 nodes, through their principles, establish an
operational mechanism to connect QRM and KM. As one repeats cycling through the RKI Cycle,
knowledge (as it becomes available), is fed into the QRM process, and facilitates RBDM. The
cyclical and infinite nature of the RKI Cycle ensures the best knowledge available is always flowing
into the quality risk management process, supporting enhanced RBDM during QRM, while also
enabling risk-informed decisions to occur through all other processes in the PQS, such as
Continuous Improvement, Change Control, Management Review, CAPA, etc.

9. Conclusion
Through a review of older and current ICH guidance on QRM and PQS (ICH Q9 and Q10
documents and associated publications) the authors have demonstrated an interdependence
between knowledge and risk in relation to effective risk-based decision-making (RBDM). A key
conclusion from this analysis reveals a repetitive and persistent connection on both:
i.

The use and application of knowledge to reduce uncertainty5 and potential harm to
patients

ii.

The need for effective knowledge management to support improved risk assessment
and effective RBDM.

Indeed, the concepts in the revised draft ICH Q9(R1) document and its associated training
materials request are aligned with ongoing work by the PRST. With knowledge emerging as an
important enabler for effective QRM and RBDM, the authors propose that the RKI Cycle could be
an important framework to support realisation of the goals of ICH Q9(R1), and indeed of ICH Q10.

5

The authors acknowledge the concept of uncertainty is a broad concept. For the purposes of this paper, the authors
are addressing epistemic uncertainty, meaning uncertainty due to lack or incompleteness of information
(https://www.nrc.gov/reading-rm/basic-ref/glossary/epistemic.html)
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As discussed in the body of this paper, the RKI Cycle is a framework to ensure the best knowledge
is applied to QRM, and that QRM knowledge is effectively managed. Its intent is that simple!
Furthermore, the authors propose that application of the RKI Cycle can lead to several benefits
in relation to RBDM and ultimately patient protection, such as:
•

An increased level of understanding

•

A decreased level of uncertainty

•

An increased accuracy of risk estimation

•

A decreased potential for patient harm.

Figure 12 below illustrates these anticipated benefits which are enhanced by repeated
application of the RKI Cycle.

Figure 12 – Anticipated benefits of RKI Cycle applied to RBDM
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